HRP20240069T1 - Adjuvantno liječenje her2-pozitivnog raka dojke - Google Patents
Adjuvantno liječenje her2-pozitivnog raka dojke Download PDFInfo
- Publication number
- HRP20240069T1 HRP20240069T1 HRP20240069TT HRP20240069T HRP20240069T1 HR P20240069 T1 HRP20240069 T1 HR P20240069T1 HR P20240069T T HRP20240069T T HR P20240069TT HR P20240069 T HRP20240069 T HR P20240069T HR P20240069 T1 HRP20240069 T1 HR P20240069T1
- Authority
- HR
- Croatia
- Prior art keywords
- pertuzumab
- trastuzumab
- chemotherapy
- combination
- administered
- Prior art date
Links
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 title 1
- 238000009098 adjuvant therapy Methods 0.000 title 1
- 229960002087 pertuzumab Drugs 0.000 claims 29
- 229960000575 trastuzumab Drugs 0.000 claims 28
- 238000002512 chemotherapy Methods 0.000 claims 23
- 238000000034 method Methods 0.000 claims 17
- 238000001990 intravenous administration Methods 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 229960004397 cyclophosphamide Drugs 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- 208000030776 invasive breast carcinoma Diseases 0.000 claims 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229960001904 epirubicin Drugs 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 108091008039 hormone receptors Proteins 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 230000003321 amplification Effects 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Claims (16)
1. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom, naznačen time, da je za uporabu u postupku za smanjivanje rizika od povratka invazivnog raka dojke ili od smrti pacijenata kojima je dijagnosticiran HER2-pozitivni rani rak dojke (eBC) u usporedbi s primjenom trastuzumaba i kemoterapije, bez pertuzumaba, pri čemu postupak obuhvaća davanje navedenim pacijentima poslije operativnog zahvata raka dojke, pertuzumaba u kombinaciji s trastuzumabom i kemoterapijom, dok pacijenti imaju rani rak dojke pozitivan na limfne čvorove, s time, da se kemoterapija bira od sljedećih
a) 5-fluorouracil + epirubicin + ciklofosfamid ili 5-fluorouracil + doksorubicin + ciklofosfamid, pri čemu kemoterapija nadalje sadrži primjenu docetaksela ili paklitaksela; ili
b) doksorubicin + ciklofosfamid ili epirubicin + ciklofosfdamid, pri čemu kemoterapija nadalje sadrži primjenu docetaksela ili paklitaksela; ili
c) docetaksel + karboplatin.
2. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom za uporabu u postupku prema patentnom zahtjevu 1, naznačen time, da pacijenti ostaju na životu bez povratka invazivnog raka dojke najmanje jednu godinu, najmanje dvije godine, ili najmanje tri godine nakon spomenute primjene.
3. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom za uporabu u postupku prema patentnom zahtjevu 1 ili 2, naznačen time, da je rak dojke kod pacijenata negativan na hormonski receptor (HR).
4. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom za uporabu u postupku prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je rizik od povratka invazivnog raka dojke ili od smrti smanjen najmanje za oko 5%, ili najmanje za oko 10%, ili najmanje za oko 15%, ili najmanje za oko 20%, ili najmanje za oko 25%, u usporedbi s primjenom trastuzumaba i kemoterapije, bez pertuzumaba.
5. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom za uporabu u postupku prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu HER2 pozitivan rak je naznačen razinom ekspresije HER2 od IHC 2+ ili 3+.
6. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom za uporabu u postupku prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da je rak HER2-amplificiran, opcionalno gdje se HER2 amplifikacija utvrđuje putem fluorescentne in situ hibridizacije (FISH).
7. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom za uporabu u postupku prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da se pertuzumab i trastuzumab primjenjuju intravenozno.
8. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom za uporabu u postupku prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da se pertuzumab i trastuzumab primjenjuju svaka tri tjedna.
9. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom za uporabu u postupku prema patentnom zahtjevu 8, naznačen time, da se pertuzumab daje kao 840 mg IV udarna doza, nakon čega slijedi 420 mg, što se daje putem IV svaka tri tjedna.
10. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom za uporabu u postupku prema patentnom zahtjevu 8 ili 9, naznačen time, da se trastuzumab daje kao 8 mg/kg intravenozna (IV) udarna doza, nakon čega slijedi 6 mg/kg, što se daje putem IV infuzije svaka tri tjedna.
11. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom za uporabu u postupku prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da se barem jedan od pertuzumaba i trastuzumaba primjenjuje supkutano.
12. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom za uporabu u postupku prema patentnom zahtjevu 11, naznačen time, da se pertuzumab daje supkutano s udarnom dozom od 1200 mg, nakon čega slijedi 600 mg svaka tri tjedna.
13. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom za uporabu u postupku prema patentnom zahtjevu 11 ili 12, naznačen time, da se pertuzumab i trastuzumab daju zajedno supkutano kao dvije odvojene supkutane injekcije.
14. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom za uporabu u postupku prema patentnom zahtjevu 11 ili 12, naznačen time, da se pertuzumab i trastuzumab daju kao jedinstvena supkutana injekcija, opcionalno pritom se pertuzumab i trastuzumab daju kao jedinstvena zajednička formulacija za supkutanu primjenu.
15. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom za uporabu u postupku prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da se pertuzumab i trastuzumab primjenjuju u vremenu od najmanje 52 tjedna.
16. Pertuzumab u kombinaciji s trastuzumabom i kemoterapijom za uporabu u postupku prema bilo kojem od patentnih zahtjeva 1 do 15, naznačen time, da primjena pertuzumaba i trastuzumaba slijedi nakon kemoterapije.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762466239P | 2017-03-02 | 2017-03-02 | |
| US201762469317P | 2017-03-09 | 2017-03-09 | |
| US201762486876P | 2017-04-18 | 2017-04-18 | |
| EP18712044.9A EP3589661B1 (en) | 2017-03-02 | 2018-02-28 | Adjuvant treatment of her2-positive breast cancer |
| PCT/US2018/020154 WO2018160654A2 (en) | 2017-03-02 | 2018-02-28 | Adjuvant treatment of her2-positive breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240069T1 true HRP20240069T1 (hr) | 2024-03-29 |
Family
ID=61691568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240069TT HRP20240069T1 (hr) | 2017-03-02 | 2018-02-28 | Adjuvantno liječenje her2-pozitivnog raka dojke |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US11077189B2 (hr) |
| EP (2) | EP4368199A3 (hr) |
| JP (4) | JP6992081B2 (hr) |
| KR (4) | KR20220100996A (hr) |
| CN (5) | CN116531511A (hr) |
| AU (3) | AU2018227788B2 (hr) |
| CA (1) | CA3048918C (hr) |
| DK (1) | DK3589661T5 (hr) |
| ES (1) | ES2969041T3 (hr) |
| FI (1) | FI3589661T3 (hr) |
| HR (1) | HRP20240069T1 (hr) |
| HU (1) | HUE064898T2 (hr) |
| IL (3) | IL289297B2 (hr) |
| LT (1) | LT3589661T (hr) |
| MX (2) | MX388169B (hr) |
| PL (1) | PL3589661T3 (hr) |
| PT (1) | PT3589661T (hr) |
| RS (1) | RS65204B1 (hr) |
| SI (1) | SI3589661T1 (hr) |
| SM (1) | SMT202400129T1 (hr) |
| TW (3) | TWI792743B (hr) |
| WO (1) | WO2018160654A2 (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60042693D1 (de) * | 1999-08-27 | 2009-09-17 | Genentech Inc | Dosierung für die behandlung mit anti erbb2-antikörpern |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| KR20200085942A (ko) | 2013-04-16 | 2020-07-15 | 제넨테크, 인크. | 페르투주맙 변이체 및 그의 평가 |
| US10380152B2 (en) * | 2016-01-19 | 2019-08-13 | International Business Machines Corporation | Cognitive system comparison and recommendation engine |
| MY189536A (en) | 2017-01-17 | 2022-02-16 | Hoffmann La Roche | Subcutaneous her2 antibody formulations |
| JP6992081B2 (ja) | 2017-03-02 | 2022-02-03 | ジェネンテック， インコーポレイテッド | Ｈｅｒ２陽性乳癌のアジュバント治療 |
| WO2020022791A1 (ko) | 2018-07-25 | 2020-01-30 | (주)알테오젠 | 신규 히알루론산 가수분해 효소 변이체 및 이를 포함하는 약제학적 조성물 |
| CN116870164B (zh) * | 2019-03-25 | 2024-07-23 | 阿特根公司 | 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物 |
| EP3947719A4 (en) * | 2019-03-29 | 2023-01-04 | The Board of Trustees of the Leland Stanford Junior University | Methods of treatments based upon anthracycline responsiveness |
| CA3137480A1 (en) * | 2019-05-02 | 2020-11-05 | Mab Discovery Gmbh | Combination of her2 antibodies |
| WO2021243123A1 (en) * | 2020-05-29 | 2021-12-02 | Seagen Inc. | Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy |
| CN115916834A (zh) * | 2020-06-29 | 2023-04-04 | 基因泰克公司 | 帕妥珠单抗加曲妥珠单抗的固定剂量组合 |
| JP7622088B2 (ja) | 2020-08-07 | 2025-01-27 | アルテオジェン・インコーポレイテッド | 組換えヒアルロニダーゼの生産方法 |
| CN113943805A (zh) * | 2021-11-02 | 2022-01-18 | 上海市生物医药技术研究院 | 基因突变检测引物组及其用途 |
| CN117224689B (zh) * | 2023-11-16 | 2024-02-23 | 上海复宏汉霖生物技术股份有限公司 | 联合抗her2抗体和化疗剂治疗胃癌的用途 |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3587657D1 (de) | 1984-01-30 | 1993-12-23 | Imp Cancer Res Tech | Verbesserungen an wachstumsfaktoren. |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| CA1339946C (en) | 1987-03-31 | 1998-07-07 | Michael J. Griffith | Ultrapurification process for polypeptides |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1990014357A1 (en) | 1989-05-19 | 1990-11-29 | Genentech, Inc. | Her2 extracellular domain |
| WO1991005264A1 (en) | 1989-09-29 | 1991-04-18 | Oncogenetics Partners | Detection and quantification of neu related proteins in the biological fluids of humans |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| DK2275119T3 (da) | 1995-07-27 | 2013-11-11 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US7371376B1 (en) | 1996-10-18 | 2008-05-13 | Genentech, Inc. | Anti-ErbB2 antibodies |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| PT1900751E (pt) | 1996-11-27 | 2010-02-23 | Genentech Inc | Purificação por afinidade de um polipéptido numa matriz de proteína a |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| WO1999048527A1 (en) | 1998-03-27 | 1999-09-30 | Genentech, Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
| CN1305896C (zh) | 1998-05-06 | 2007-03-21 | 基因技术股份有限公司 | 用离子交换层析纯化蛋白质 |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| AU782325B2 (en) | 1999-05-14 | 2005-07-21 | Genentech Inc. | Treatment with anti-ErbB2 antibodies |
| BRPI0012198B8 (pt) | 1999-06-25 | 2021-05-25 | Genentech Inc | anticorpos humanizados, composição e imunoconjugado |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| IL147017A0 (en) | 1999-06-25 | 2002-08-14 | Genentech Inc | TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| DE60042693D1 (de) | 1999-08-27 | 2009-09-17 | Genentech Inc | Dosierung für die behandlung mit anti erbb2-antikörpern |
| US20200048362A1 (en) | 2000-03-16 | 2020-02-13 | Immunogen, Inc. | Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| KR20130056201A (ko) | 2000-05-19 | 2013-05-29 | 제넨테크, 인크. | ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
| US20030232399A1 (en) | 2000-06-14 | 2003-12-18 | Robertson John Forsyth Russell | Cancer detection methods and reagents |
| US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
| WO2002072636A2 (en) | 2000-12-28 | 2002-09-19 | Altus Biologics Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| US6695940B2 (en) | 2001-04-05 | 2004-02-24 | Alan D. Devoe | Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells |
| AU2002355419A1 (en) | 2001-08-06 | 2003-02-24 | Genomed, Llc | Methods and compositions for treating diseases associated with excesses in ace |
| EP1300146A1 (en) | 2001-10-03 | 2003-04-09 | Boehringer Ingelheim International GmbH | Pharmaceutical composition for the treatment of animal mammary tumors |
| US20040048525A1 (en) | 2002-01-28 | 2004-03-11 | Sagucio Esteban N. | Watercycle for wet rider |
| ES2401428T3 (es) | 2002-04-10 | 2013-04-19 | Genentech, Inc. | Variantes de anticuerpos anti-HER2 |
| CA2486124A1 (en) | 2002-05-17 | 2003-11-27 | Aventis Pharma S.A. | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer |
| BR0312534A (pt) | 2002-07-15 | 2007-03-13 | Genentech Inc | método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura |
| US6982719B2 (en) | 2002-07-15 | 2006-01-03 | Sun Microsystems, Inc. | Switching sample buffer context in response to sample requests for real-time sample filtering and video generation |
| US7129840B2 (en) | 2002-09-03 | 2006-10-31 | Ricoh Company, Ltd. | Document security system |
| EP2332996B1 (en) | 2002-09-11 | 2014-10-15 | Genentech, Inc. | Purification of anti-Her2 antibodies |
| US20060100168A1 (en) | 2002-09-30 | 2006-05-11 | The Trustee Of Boston University | Method of treating cancer using adenosine and its analogs |
| EP1572972A4 (en) | 2002-11-21 | 2007-11-21 | Genentech Inc | THERAPY OF NON-MALIGNER DISEASES OR DISORDER WITH ANTI-ERBB2 ANTIBODIES |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| WO2004098508A2 (en) | 2003-04-30 | 2004-11-18 | Napro Biotherapeutics, Inc. | Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells |
| SI3095793T1 (sl) | 2003-07-28 | 2020-07-31 | Genentech, Inc. | Zmanjšanje izluževanja proteina A med afinitetno kromatografijo proteina A |
| US20060034840A1 (en) | 2004-04-08 | 2006-02-16 | Agus David B | ErbB antagonists for pain therapy |
| JP4879884B2 (ja) | 2004-04-12 | 2012-02-22 | メディミューン，エルエルシー | 抗−ｉｌ−９抗体製剤及びその使用法 |
| US7195440B2 (en) | 2004-05-27 | 2007-03-27 | Lambert Charles F | Agricultural silo auger system apparatus and method |
| RU2404810C9 (ru) | 2004-06-01 | 2015-06-20 | Дженентек, Инк. | Конъюгаты антитело-лекарственное средство и способы |
| GT200500155A (es) | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
| KR20190035967A (ko) | 2004-07-22 | 2019-04-03 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| ZA200701715B (en) | 2004-08-19 | 2008-07-30 | Genentech Inc | Polypeptide variants with altered effector function |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP2008518902A (ja) | 2004-11-04 | 2008-06-05 | ファイザー・プロダクツ・インク | 乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療 |
| KR20070085855A (ko) | 2004-12-07 | 2007-08-27 | 제넨테크, 인크. | Ｈｅｒ 억제제를 이용한 치료를 위한 환자 선택 방법 |
| KR20150083139A (ko) | 2005-01-21 | 2015-07-16 | 제넨테크, 인크. | Ｈｅｒ 항체의 고정 용량 투여법 |
| CA2598239C (en) | 2005-02-18 | 2019-10-29 | Abraxis Bioscience, Inc. | Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy |
| DK1850874T3 (da) | 2005-02-23 | 2013-11-11 | Genentech Inc | Forlængelse af tid til sygdomsprogression eller overlevelse for ovariecancer ved anvendelse af pertuzumab |
| US20060204505A1 (en) | 2005-03-08 | 2006-09-14 | Sliwkowski Mark X | Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs) |
| US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US20070009976A1 (en) | 2005-07-06 | 2007-01-11 | Helmut Lenz | Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
| WO2007067597A2 (en) | 2005-12-05 | 2007-06-14 | Trinity Biosystems, Inc. | Methods and compositions for needleless delivery of binding partners |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| CA2652999A1 (en) | 2006-05-31 | 2007-12-13 | Thallion Pharmaceuticals Incorporated | Methods, compositions, and kits for treating shiga toxin associated conditions |
| JP2009539836A (ja) | 2006-06-05 | 2009-11-19 | ジェネンテック・インコーポレーテッド | ＥＧＦまたはＴＧＦ−αのレベルの上昇が生じている癌患者の生存の延長 |
| CL2007002404A1 (es) | 2006-08-21 | 2008-04-18 | Hoffmann La Roche | Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2. |
| WO2008031531A1 (en) | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| NZ578824A (en) | 2007-03-02 | 2012-03-30 | Genentech Inc | Predicting response to a her dimerisation inhibitor based on low her3 expression |
| EP1997534A1 (en) | 2007-05-31 | 2008-12-03 | Pierre Fabre Medicament | Cancer treatment combination therapy comprising vinflunine and trastuzumab |
| BRPI0812777A2 (pt) | 2007-06-06 | 2014-12-02 | Hoffmann La Roche | Composição de um primeiro anticorpo monoclonal não-marcado que se liga a um antígeno de tumor e de um segundo anticorpo monoclonal que não sofre reação cruzada marcado com um marcador fluorescente nir |
| SI2171090T1 (sl) | 2007-06-08 | 2013-07-31 | Genentech, Inc. | Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| KR101584823B1 (ko) | 2007-09-12 | 2016-01-22 | 제넨테크, 인크. | 포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법 |
| EP2211854A4 (en) | 2007-10-19 | 2011-01-12 | Bipar Sciences Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS |
| TWI554517B (zh) | 2007-10-30 | 2016-10-21 | 建南德克公司 | 藉陽離子交換層析法純化抗體 |
| NZ586125A (en) | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| US20090203015A1 (en) | 2008-02-13 | 2009-08-13 | Celera Corporation | Multiplex assays for hormonal and growth factor receptors, and uses thereof |
| AU2009221729A1 (en) | 2008-03-06 | 2009-09-11 | Genentech, Inc. | Combination therapy with c-met and HER antagonists |
| ES2629405T3 (es) | 2008-03-18 | 2017-08-09 | Genentech, Inc. | Combinaciones de un conjugado de fármaco-anticuerpo anti-HER2 y docetaxel |
| US9235334B2 (en) | 2008-05-09 | 2016-01-12 | Genesis Industries, Llc | Managing landbases and machine operations performed thereon |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| US20110256149A1 (en) | 2008-10-09 | 2011-10-20 | Medimmune, Llc | Antibody formulation |
| DK2361085T4 (en) | 2008-11-22 | 2018-10-08 | Hoffmann La Roche | USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER |
| MX2011009312A (es) | 2009-03-06 | 2012-02-29 | Medimmune Llc | Formulaciones de anticuerpos humanizados anti-cd19. |
| WO2010136569A1 (en) | 2009-05-29 | 2010-12-02 | F. Hoffmann-La Roche Ag | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AU2010299816C1 (en) | 2009-09-28 | 2018-02-01 | F. Hoffmann-La Roche Ag | Benzoxazepin PI3K inhibitor compounds and methods of use |
| WO2011069074A2 (en) | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| BR112013014316A2 (pt) | 2010-12-09 | 2016-09-27 | Genentech Inc | tratamento de câncer her2-positivo com paclitaxel e trastuzumabe-mcc-dm1 |
| JP6385060B2 (ja) | 2011-03-07 | 2018-09-05 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 治療的に活性な抗体のインビボにおける選択 |
| FI4241849T3 (fi) | 2011-10-14 | 2024-11-12 | Hoffmann La Roche | Her2:n dimerisaation estäjä pertutsumabin käyttötapoja ja sitä sisältävä tuote |
| EP2788500A1 (en) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| EP2793941A1 (en) | 2011-12-23 | 2014-10-29 | F.Hoffmann-La Roche Ag | Articles of manufacture and methods for co-administration of antibodies |
| SG11201407537YA (en) | 2012-06-08 | 2014-12-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| HUE044789T2 (hu) | 2012-08-17 | 2019-11-28 | Hoffmann La Roche | Cobimetinib és vemurafenib beadását magukban foglaló kombinált terápiák melanóma kezelésére |
| BR112015012644A2 (pt) | 2012-11-30 | 2017-12-19 | Hoffmann La Roche | método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit; |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| KR20200085942A (ko) | 2013-04-16 | 2020-07-15 | 제넨테크, 인크. | 페르투주맙 변이체 및 그의 평가 |
| AU2014364601A1 (en) | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Methods of treating HER2-positive cancers using PD-1 axis binding antagonists and anti-HER2 antibodies |
| WO2015164665A1 (en) * | 2014-04-25 | 2015-10-29 | Genentech, Inc. | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
| CN113607945B (zh) | 2015-07-07 | 2025-01-28 | 豪夫迈·罗氏有限公司 | 抗HER2抗体-药物缀合物和Bcl-2抑制剂的组合疗法 |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| FR3056576B1 (fr) | 2016-09-29 | 2020-02-07 | Easyl | Procede de fabrication de diglyceroxyde de calcium |
| US20180134803A1 (en) * | 2016-11-04 | 2018-05-17 | Genentech, Inc. | Treatment of her2-positive breast cancer |
| CN110099926A (zh) | 2016-12-28 | 2019-08-06 | 豪夫迈·罗氏有限公司 | 晚期her2表达性癌症的治疗 |
| MY189536A (en) | 2017-01-17 | 2022-02-16 | Hoffmann La Roche | Subcutaneous her2 antibody formulations |
| JP6992081B2 (ja) * | 2017-03-02 | 2022-02-03 | ジェネンテック， インコーポレイテッド | Ｈｅｒ２陽性乳癌のアジュバント治療 |
| BR112020007470A2 (pt) | 2017-10-20 | 2020-10-27 | Biontech Rna Pharmaceuticals Gmbh | métodos para produzir um colóide de lipossoma, para preparar partículas, para a fabricação de fluxo contínuo, para preparar uma composição congelada e para preparar uma composição aquosa, colóide de lipossoma, composições, composição congelada e composição aquosa |
| CN115916834A (zh) | 2020-06-29 | 2023-04-04 | 基因泰克公司 | 帕妥珠单抗加曲妥珠单抗的固定剂量组合 |
| KR20230037560A (ko) | 2020-07-14 | 2023-03-16 | 에프. 호프만-라 로슈 아게 | 고정 용량 조합에 대한 분석 |
| MX2023006793A (es) | 2020-12-11 | 2023-06-20 | Genentech Inc | Tratamientos conjuntos para tratamiento de cancer her2. |
| EP4493180A1 (en) | 2022-03-14 | 2025-01-22 | Genentech Inc. | Combination therapies for breast cancer |
-
2018
- 2018-02-28 JP JP2019547135A patent/JP6992081B2/ja active Active
- 2018-02-28 KR KR1020227022617A patent/KR20220100996A/ko not_active Ceased
- 2018-02-28 CN CN202310488287.6A patent/CN116531511A/zh active Pending
- 2018-02-28 DK DK18712044.9T patent/DK3589661T5/da active
- 2018-02-28 CN CN201880014322.8A patent/CN110337450B/zh active Active
- 2018-02-28 CN CN202311196502.1A patent/CN117180422A/zh active Pending
- 2018-02-28 EP EP23205007.0A patent/EP4368199A3/en active Pending
- 2018-02-28 WO PCT/US2018/020154 patent/WO2018160654A2/en not_active Ceased
- 2018-02-28 PT PT187120449T patent/PT3589661T/pt unknown
- 2018-02-28 IL IL289297A patent/IL289297B2/en unknown
- 2018-02-28 MX MX2019010296A patent/MX388169B/es unknown
- 2018-02-28 ES ES18712044T patent/ES2969041T3/es active Active
- 2018-02-28 EP EP18712044.9A patent/EP3589661B1/en active Active
- 2018-02-28 SM SM20240129T patent/SMT202400129T1/it unknown
- 2018-02-28 CA CA3048918A patent/CA3048918C/en active Active
- 2018-02-28 PL PL18712044.9T patent/PL3589661T3/pl unknown
- 2018-02-28 FI FIEP18712044.9T patent/FI3589661T3/fi active
- 2018-02-28 IL IL301279A patent/IL301279B2/en unknown
- 2018-02-28 CN CN202310813342.4A patent/CN116850283A/zh active Pending
- 2018-02-28 AU AU2018227788A patent/AU2018227788B2/en active Active
- 2018-02-28 KR KR1020237033237A patent/KR20230144110A/ko not_active Ceased
- 2018-02-28 KR KR1020197020413A patent/KR20190096384A/ko not_active Ceased
- 2018-02-28 CN CN202210489702.5A patent/CN114984206A/zh not_active Withdrawn
- 2018-02-28 HU HUE18712044A patent/HUE064898T2/hu unknown
- 2018-02-28 US US15/907,718 patent/US11077189B2/en active Active
- 2018-02-28 LT LTEPPCT/US2018/020154T patent/LT3589661T/lt unknown
- 2018-02-28 SI SI201831055T patent/SI3589661T1/sl unknown
- 2018-02-28 RS RS20240083A patent/RS65204B1/sr unknown
- 2018-02-28 KR KR1020217027734A patent/KR102417583B1/ko active Active
- 2018-02-28 HR HRP20240069TT patent/HRP20240069T1/hr unknown
- 2018-03-01 TW TW110145536A patent/TWI792743B/zh active
- 2018-03-01 TW TW112106134A patent/TWI831617B/zh active
- 2018-03-01 TW TW107106709A patent/TWI748062B/zh active
-
2019
- 2019-07-31 IL IL268394A patent/IL268394B2/en unknown
- 2019-08-29 MX MX2021014137A patent/MX2021014137A/es unknown
-
2021
- 2021-07-09 US US17/305,556 patent/US11992529B2/en active Active
- 2021-07-15 AU AU2021205081A patent/AU2021205081B2/en active Active
- 2021-10-26 JP JP2021174654A patent/JP7270701B2/ja active Active
-
2022
- 2022-08-22 US US17/821,270 patent/US11638756B2/en active Active
-
2023
- 2023-02-07 JP JP2023016713A patent/JP2023071672A/ja active Pending
- 2023-09-25 JP JP2023160008A patent/JP2024001062A/ja active Pending
- 2023-10-02 AU AU2023237217A patent/AU2023237217B2/en active Active
-
2024
- 2024-04-16 US US18/637,283 patent/US12128103B2/en active Active
- 2024-09-23 US US18/893,603 patent/US20250018032A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240069T1 (hr) | Adjuvantno liječenje her2-pozitivnog raka dojke | |
| Kudrimoti et al. | Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study | |
| Di Lorenzo et al. | Castration-resistant prostate cancer: current and emerging treatment strategies | |
| JP2020515519A5 (hr) | ||
| ES2644022T3 (es) | Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso | |
| KR102225371B1 (ko) | 플리나불린 및 탁산의 조합에 의한 암 치료 | |
| HRP20201866T1 (hr) | Formulacije protutijela za her2 za supkutanu primjenu | |
| IL299376A (en) | Pertuzuniab plus trastuzumab fixed dose combination | |
| US20220226474A1 (en) | Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer | |
| CN111867629A (zh) | 抗her2抗体-药物偶联物在治疗癌症中的用途 | |
| JP2020502182A5 (hr) | ||
| JP6489517B2 (ja) | ガン幹細胞に対する分化促進薬及び脳腫瘍治療薬 | |
| JP2018513202A (ja) | 抗ｆｕｇｅｔａｃｔｉｃ剤と免疫療法薬の併用療法、および、癌の治療のための組成物 | |
| TWI798243B (zh) | 治療癌症的方法 | |
| RU2524309C1 (ru) | Способ выбора тактики лечения местно-распространенного рака предстательной железы | |
| Leon-Ferre et al. | Extravasation of oxaliplatin into the mediastinum: a case report and review of the literature | |
| JPWO2014050912A1 (ja) | 二酸化炭素を溶解した液状医薬とそれを用いる治療方法 | |
| Okamoto | Bevacizumab/paclitaxel | |
| AU2016253153A1 (en) | Compositions for the treatment of cancer | |
| Moloney et al. | Cetuximab extravasation | |
| RU2548718C1 (ru) | Способ профилактики родильного пареза у коров | |
| Walczak et al. | PCN93 treatment of well-differentiated pancreatic neuroendocrine tumors with sunitinib in patients with disease progression: cost-utility and cost-effectiveness analysis | |
| MOON | Sipuleucel-T Prolongs Survival in Prostate Cancer | |
| Hempel | Advances in HER2-Positive Gastric and Gastroesophageal Cancer: Insights from KEYNOTE-811 | |
| NZ761478A (en) | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |